By Ronda Fears
Nashville, Nov. 16 - Digene Corp. priced a follow-on offering of 3 million shares of common stock off the shelf at $28.00 per share, discounted from Tuesday's closing level of $28.33, via bookrunner J.P. Morgan.
Gaithersburg, Md.-based Digene develops DNA and RNA testing systems with a focus on women's cancers and infectious diseases.
Proceeds are earmarked for working capital and other general corporate purposes, including research and development expenditures, sales and marketing expenditures, capital expenditures and potential acquisitions.
Digene primary shareholder Armonk Partners also sold 1 million shares at $28.00 each.
| Issuer: | Digene Corp.
|
| Issue: | Follow-on stock offering
|
| Gross proceeds: | $52.64 million
|
| Net proceeds: | $52.50 million
|
| Shares: | 3 million
|
| Greenshoe: | 450,000 shares
|
| Price: | $28.00 per share
|
| Bookrunner: | J.P. Morgan
|
| Joint lead manager: | Thomas Weisel Partners
|
| Co-managers: | Goldman Sachs and SG Cowen
|
| Pricing date: | Nov. 15
|
| Settlement date: | Nov. 21
|
| Ticker: | DIGE
|
| Stock price: | $28.33 at close Nov. 15
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
